Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
deals
8
×
life sciences
national blog main
sanofi
8
×
boston top stories
national top stories
biotech
clinical trials
new york blog main
new york top stories
san francisco blog main
san francisco top stories
startups
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
investing
national
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
amgen
cancer immunotherapy
eli lilly
ipo
What
medicines
bio
drug
roundup
cancer
deal
new
alzheimer’s
cash
companies
ipo
latest
molecules
pharmaceutical
potential
targets
years
acquire
acquisitions
address
adds
ago
agreed
ahead
allosteric
ambien
american
announced
annual
asco
attendees
attention
bets
billion
biotech
brings
camp’s
ceo
chicago
cholesterol
Language
unset
Current search:
sanofi
×
deals
×
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
6 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More